DIRK REDLICH, PH.D.
VACCINES PROCESS AND ANALYTICAL DEVELOPMENT
Dirk Redlich, Ph.D., is Head of Vaccines Process and Analytical Development at Janssen. Dirk’s team operates three pilot plants and vaccines launch facilities in Leiden, the Netherlands, and Bern, Switzerland. The scope of responsibility includes the process and analytical development of vaccines and clinical trial material manufacturing.
Dirk joined the Janssen Research Foundation, a Johnson & Johnson company, to lead the analytical method development in 2001. Dirk contributed to numerous early and late drug development programs in areas such as oncology and infectious disease. Accepting roles with increasing responsibilities, Dirk led activities in various areas of pharmaceutical drug development, ranging from analytical and formulation development, to program management, process excellence, and served as strategy and operations leader. Dirk has worked in Europe, Asia and the US.
As of June 2011, Dirk became part of the integration team after the acquisition of Crucell, the Vaccine company acquired by J&J in February 2011. Dirk became head of program management and strategy and operations, moving into his current role in 2014.
Dirk has authored more than 20 peer reviewed articles and book chapters. He is an active speaker at scientific conferences in the area of vaccine development and manufacturing.
Dirk received his Ph.D. in Chemistry from the Technical University of Munich and was a research fellow at the Technical University of Weihenstephan, Freising, Germany. Dirk is also an alumnus of the Harvard Business School, where he completed an advanced management program.